Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort
Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort
复制标题
DOI：
10.1111/hepr.12919
复制
发表时间：
2017-12-01
影响因子：
4.2
通讯作者：
Takehara, Tetsuo
中科院分区：
文献类型：
--
作者：
Doi, Akira;Sakamori, Ryotaro;Takehara, Tetsuo
一些病例报告表明，在直接作用抗病毒药物（DAA）治疗期间，当前或既往HBV感染的丙型肝炎患者发生乙型肝炎病毒（HBV）再激活，导致一些病例严重肝炎或死亡。然而，其确切频率和风险因素尚不完全清楚。我们分析了一个前瞻性队列。方法我们分析了461例连续接受12周基因1型雷地帕韦/索非布韦治疗或基因2型索非布韦加利巴韦林治疗的丙型肝炎患者的HBV再激活情况。结果基线保存血清检测，159例（34%）HBV核心抗体（anti-HBc）血清阳性，纳入后续分析；HBV表面抗原（HBsAg）阳性4例，阴性4例。血清HBV DNA检测不到或可检测到，但
AimSeveral case reports have shown that hepatitis B virus (HBV) reactivation developed in hepatitis C patients with a current or previous HBV infection during direct-acting antiviral (DAA) treatment, which led to severe hepatitis or death in some cases. However, its precise frequency and risk factors are not entirely clear. We analyzed a prospective cohort.MethodsWe analyzed HBV reactivation in 461 consecutive hepatitis C patients who received 12weeks of ledipasvir/sofosbuvir for genotype 1 or sofosbuvir plus ribavirin for genotype 2 at multiple centers.ResultsBy the examination of the preserved sera at baseline, 159 patients (34%) were identified as seropositive for HBV core antibody (anti-HBc) and were included in the subsequent analysis; 4 patients were positive for HBV surface antigen (HBsAg), and the others were negative. Serum HBV DNA was undetectable or was detectable but